AMBI Skincare Fade Cream Recalled for Temperature Storage Deviations
AMBI Skincare Fade Cream is being recalled nationwide due to cGMP violations. The product was stored outside its labeled temperature requirements during manufacturing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a Class II FDA recall involving improper storage conditions that could compromise product safety or efficacy. Although no illnesses or injuries have been reported, the manufacturing deviation represents a risk-of-harm scenario, placing it in the High severity category per FDA classification guidelines.
Plain-English summary
AMBI Skincare Fade Cream Normal Skin (2 oz / 56g) is being recalled nationwide. The recall was initiated following a cGMP violation: the product was stored outside its labeled temperature requirements during manufacturing. The affected product can be identified by SKU 2024222 and was distributed throughout the United States.
Family Dollar Stores, Llc., the recalling firm, initiated this recall. Consumers with questions or concerns about this recall should contact the FDA or consult the FDA's drug recall database for additional information.
The recalled product
- Product
- AMBI Skincare Fade Cream Normal Skin, Net Wt. 2 OZ. (56g)
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Topical Skincare
- Hazard
- temperature-deviation
- improper-storage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- SKUs 2024222
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27